Status:
COMPLETED
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate the impact of gastroesophageal reflux disease (GERD) treatment in primary care setting on symptom control and daily life in symptomatic GERD patients, using bo...
Detailed Description
A prospective, observational study to describe symptom control and impact on daily life in patients with gastroesophageal reflux disease (GERD)
Eligibility Criteria
Inclusion
- Patients known or newly diagnosed with GERD
- Patients with typical GERD symptoms as heartburn and regurgitation for ≥2 days in the previous week
- Patients, currently not treated with a proton pump inhibitor
Exclusion
- Patients who have been receiving treatment with non-steroidal antiinflammatory drugs within two weeks prior the inclusion in the study
- Patients with medical history of surgery of the esophagus, stomach or duodenum
- Pregnant or nursing females
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT01432392
Start Date
September 1 2011
End Date
April 1 2012
Last Update
May 10 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sofia, Bulgaria
2
Varna, Bulgaria